Literature DB >> 36269419

[Second opinions and reference pathology in breast cancer].

Hans H Kreipe1.   

Abstract

Second opinion in pathology recruits expert knowledge for the diagnosis in difficult cases and has a tradition in Germany with generation of a network between primarily diagnostic and academic institutes of pathology, active in research. The term reference pathology does mean a label for a class of institutes for pathology but rather specifies a function within prospective clinical trials with defined endpoints and a central pathology, which will derive expert knowledge from this function. On either way generated collection of samples and expertise will enable diagnostic support in difficult cases. Furthermore, research based on this tissue material might lead to the establishment of novel biomarkers and methods, which when transferred to decentral application will enhance diagnostic validity of pathological tissue analysis as a whole. Thus, for all institutes participating in the network, pathology as a diagnostic discipline and patients, second opinion and reference pathology provide considerable benefit with regard to quality of histopathological diagnoses.
© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Entities:  

Keywords:  Biomarker; Breast tumors; Consultation pathology; Quality assurance; Therapy studies

Year:  2022        PMID: 36269419     DOI: 10.1007/s00292-022-01144-7

Source DB:  PubMed          Journal:  Pathologie (Heidelb)        ISSN: 2731-7188


  1 in total

1.  Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer.

Authors:  Ulrike A Nitz; Oleg Gluz; Sherko Kümmel; Matthias Christgen; Michael Braun; Bahriye Aktas; Kerstin Lüdtke-Heckenkamp; Helmut Forstbauer; Eva-Maria Grischke; Claudia Schumacher; Maren Darsow; Katja Krauss; Benno Nuding; Marc Thill; Jochem Potenberg; Christoph Uleer; Mathias Warm; Hans Holger Fischer; Wolfram Malter; Michael Hauptmann; Ronald E Kates; Monika Gräser; Rachel Würstlein; Steven Shak; Frederick Baehner; Hans H Kreipe; Nadia Harbeck
Journal:  J Clin Oncol       Date:  2022-04-11       Impact factor: 50.717

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.